Locally Advanced Pancreatic Adenocarcinoma: Where Are We and Where Are We Going?
Abstract
Eight abstracts highlighting the continued evolution of the management of locally advanced pancreatic cancer were presented at the 2011 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium (Abstracts #195, #239, #259, #281, #287, #305, #307, #324). These studies address key issues including the role of novel targeted therapies, what chemotherapy regimen should be used in conjunction with radiotherapy, and whether locally advanced pancreatic cancer can be managed with chemotherapy alone.
Image: Yale University. New Haven, CT, USA. (logo)
Downloads
References
Loehrer PJ Sr, Powell ME, Cardenes HR, Wagner L, Brell JM, Ramanathan RK, et al. A randomized phase III study of gemcitabine in combination with radiation therapy versus gemcitabine alone in patients with localized, unresectable pancreatic cancer: E4201. J Clin Oncol 2008; 26(15 Suppl.):Abstract 4506.
Heinemann V, Labianca R, Hinke A, Louvet C. Increased survival using platinum analog combined with gemcitabine as compared to single-agent gemcitabine in advanced pancreatic cancer: pooled analysis of two randomized trials, the GERCOR/GISCAD intergroup study and a German multicenter study. Ann Oncol 2007; 18:1652-9. [PMID 17660491]
Huguet F, André T, Hammel P, Artru P, Balosso J, Selle F, et al. Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies. J Clin Oncol 2007; 25:326-31. [PMID 17235048]
Bloomston M, Marsh C, Walker J, Coyle W, Marx H, Tahiri S, et al. Phase I trial of gene-mediated cytotoxic immunotherapy in combination with chemoradiation for locally advanced pancreatic cancer. J Clin Oncol 2011; 29(Suppl. 4):Abstract 195.
Czito BG, Willett C, Kennedy-Newton P, Tyler DS, Hurwitz H, Uronis HE. A phase I study of erlotinib, bevacizumab, and external beam radiation therapy (RT) for patients with localized pancreatic carcinoma (PC). J Clin Oncol 2011; 29(Suppl. 4):Abstract 281.
Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007; 25:1960-6. [PMID 17452677]
Chang KJ, Fisher W, Kenady D, Klapman J, Posner M, Reid T, et al. Multicenter randomized controlled phase III clinical trial using TNFerade (TNF) with chemoradiation (CRT) in patients with locally advanced pancreatic cancer (LAPC): Interim analysis (IA) of overall survival (OS). J Clin Oncol 2009; 27(15 Suppl.):Abstract 4605.
Sudo K, Yamaguchi T, Ishihara T, Nakamura K, Hara T, Denda T, et al. Phase II study of oral S-1 and concurrent radiotherapy in patients with unresectable locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 2010 Jun 2. [PMID 20605363]
Crane CH, Winter K, Regine WF, Safran H, Rich TA, Curran W, et al. Phase II study of bevacizumab with concurrent capecitabine and radiation followed by maintenance gemcitabine and bevacizumab for locally advanced pancreatic cancer: Radiation Therapy Oncology Group RTOG 0411. J Clin Oncol 2009; 27:4096-102. [PMID 19636002]
Anderson S, Cardenes HR, Akisik F, Johnston EL, Clark R, Perkins SM, et al. Phase I study of sorafenib (S) with gemcitabine (G)-based radiotherapy (G-RT) in patients (pts) with locally advanced unresectable pancreatic adenocarcinoma (LAUPC). J Clin Oncol 2010: 28(15 Suppl.):Abstract 4139.
Rich T, Harris J, Abrams R, Erickson B, Doherty M, Paradelo J, et al. Phase II study of external irradiation and weekly paclitaxel for nonmetastatic, unresectable pancreatic cancer: RTOG-98-12. Am J Clin Oncol 2004; 27:51-6. [PMID 14758134]
Brunner TB, Geiger M, Grabenbauer GG, Lang-Welzenbach M, Mantoni TS, Cavallaro A, et al. Phase I trial of the human immunodeficiency virus protease inhibitor nelfinavir and chemoradiation for locally advanced pancreatic cancer. J Clin Oncol 2008; 26:2699-706. [PMID 18509182]
Duffy A, Kortmansky J, Schwartz GK, Capanu M, Puleio S, Minsky B, et al. A phase I study of erlotinib in combination with gemcitabine and radiation in locally advanced, non-operable pancreatic adenocarcinoma. Ann Oncol 2008; 19:86-91. [PMID 17878176]
Crane CH, Varadhachary GR, Javle MM, Safran H, Krishnan S, Fleming JB, et al. Multi-institutional phase II trial of induction cetuximab, gemcitabine, and oxaliplatin, followed by radiotherapy with concurrent capecitabine, and cetuximab, for locally advanced pancreatic adenocarcinoma (LAPC). J Clin Oncol 2010; Gastrointestinal Cancers Symposium:Abstract 132.
Chinnaiyan P, Huang S, Vallabhaneni G, Armstrong E, Varambally S, Tomlins SA, et al. Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva). Cancer Res 2005; 65:3328-35. [PMID 15833866]
Gorski DH, Beckett MA, Jaskowiak NT, Calvin DP, Mauceri HJ, Salloum RM, et al. Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res 1999; 59:3374-78. [PMID 10416597]
Scappaticci FA, Fehrenbacher L, Cartwright T, Hainsworth JD, Heim W, Berlin J, et al. Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab. J Surg Oncol 2005; 91:173-80. [PMID 16118771]
Huang J, Robertson JR, Margolis JH, Balaraman S, Gustafson GS, Khilanani PV, et al. Long-term results of full-dose gemcitabine with radiation therapy compared to 5-fluorouracil with radiation therapy for locally advanced pancreatic cancer. J Clin Oncol 2011; 29(Suppl. 4):Abstract 287.
Lin C, Kos BM, Sasson AR, Meza JL, Grem JL. A phase II study of neoadjuvant gemcitabine/5-fluorouracil followed by 5-fluorouracil/oxaliplatin concurrent with radiation in patients with locally advanced pancreatic cancer. J Clin Oncol 2011; 29(Suppl. 4):Abstract 259.
Ioka T, Fukutake N, Ikezawa K, Tanaka S, Nakamura S, Nishiyama K. Concurrent chemoradiotherapy with gemcitabine and S-1 for unresectable locally advanced pancreatic adenocarcinoma: A phase I study. J Clin Oncol 2011; 29(Suppl. 4):Abstract 305.
Kim EJ, Ben-Josef E, Griffith KA, Herman JM, Wolfgang CL, Bekaii-Saab TS, et al. Phase II trial of neoadjuvant full-dose gemcitabine, oxaliplatin, and radiation (RT) in patients with resectable (R) or borderline resectable (BR) pancreatic cancer. J Clin Oncol 2011; 29(Suppl. 4):Abstract 239.
Li CP, Chao Y, Chi KH, Chan WK, Teng HC, Lee RC, et al. Concurrent chemoradiotherapy treatment of locally advanced pancreatic cancer: gemcitabine versus 5-fluorouracil, a randomized controlled study. Int J Radiat Oncol Biol Phys 2003; 57:98-104. [PMID 12909221]
Chauffert B, Mornex F, Bonnetain F, Rougier P, Mariette C, Bouché O, et al. Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000-01 FFCD/SFRO study. Ann Oncol 2008; 19:1592-9. [PMID 18467316]
Ioka T, Nakamura S, Nishiyama K. A randomized phase II study of gemcitabine 1000 mg/m2 and concurrent radiotherapy comparing gemcitabine alone for unresectable locally advanced pancreatic adenocarcinoma. Int J Radiat Oncol Biol Phys 2010; 78(3, Supplement):S102.
Ben-Josef E, Griffith K, Francis IR, Khan G, Lawrence TS, Abrams R, et al. Phase I radiation dose-escalation trial of intensity-modulated radiotherapy (IMRT) with concurrent fixed dose-rate gemcitabine (FDR-G) for unresectable pancreatic cancer. J Clin Oncol 2009; 27(15 Suppl.):Abstract 4602.
Murphy JD, Adusumilli S, Griffith KA, Ray ME, Zalupski MM, Lawrence TS, Ben-Josef E. Full-dose gemcitabine and concurrent radiotherapy for unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys 2007; 68:801-8. [PMID 17379445]
Ishii H, Okada S, Tokuuye K, Nose H, Okusaka T, Yoshimori M, et al. Protracted 5-fluorouracil infusion with concurrent radiotherapy as a treatment for locally advanced pancreatic carcinoma. Cancer 1997; 79:1516-20. [PMID 9118032]
André T, Balosso J, Louvet C, Hannoun L, Houry S, Huguier M, et al. Combined radiotherapy and chemotherapy (cisplatin and 5-fluorouracil) as palliative treatment for localized unresectable or adjuvant treatment for resected pancreatic adenocarcinoma: results of a feasibility study. Int J Radiat Oncol Biol Phys 2000; 46:903-11. [PMID 10705012]
Kornek GV, Schratter-Sehn A, Marczell A, Depisch D, Karner J, Krauss G, et al. Treatment of unresectable, locally advanced pancreatic adenocarcinoma with combined radiochemotherapy with 5-fluorouracil, leucovorin and cisplatin. Br J Cancer 2000; 82:98-103. [PMID 10638974]
Boz G, De Paoli A, Innocente R, Rossi C, Tosolini G, Pederzoli P, et al. Radiotherapy and continuous infusion 5-fluorouracil in patients with nonresectable pancreatic carcinoma. Int J Radiat Oncol Biol Phys 2001; 51:736-40. [PMID 11597816]
Crane CH, Antolak JA, Rosen II, Forster KM, Evans DB, Janjan NA, et al. Phase I study of concomitant gemcitabine and IMRT for patients with unresectable adenocarcinoma of the pancreatic head. Int J Gastrointest Cancer 2001; 30:123-32. [PMID 12540024]
Small W Jr, Berlin J, Freedman GM, Lawrence T, Talamonti MS, Mulcahy MF, et al. Full-dose gemcitabine with concurrent radiation therapy in patients with nonmetastatic pancreatic cancer: a multicenter phase II trial. J Clin Oncol 2008; 26:942-7. [PMID 18281668]
Hosein PJ, Kawamura C, Macintyre J, Loaiza-Bonilla A, Merchan JR, Levi JU, Rocha Lima CS. Pilot study of neoadjuvant FOLFIRINOX in unresectable locally advanced (LA) pancreatic carcinoma (PC). J Clin Oncol 2011; 29(Suppl. 4):Abstract 324.
Tanaka T, Nishiofuku H, Sho M, Anai H, Sueyoshi S, Yamamoto K, et al. Phase I/II study of arterial infusion with 5-fluorouracil combined with systemic gemcitabine for unresectable pancreatic cancer. J Clin Oncol 2011; 29(Suppl. 4):Abstract 307.
Conroy T, Desseigne F, Ychou M, Ducreux M, Bouche O, Guimbaud R, et al. Randomized phase III trial comparing FOLFIRINOX (F: 5FU/leucovorin (LV), irinotecan (I), and oxaliplatin (O)) versus gemcitabine (G) as first-line treatment for metastatic pancreatic adenocarcinoma (MPA): Preplanned interim analysis results of the PRODIGE 4/ACCORD 11 trial. J Clin Oncol 2010; 28(15 Suppl.):Abstract 4010.
Krishnan S, Rana V, Janjan NA, Varadhachary GR, Abbruzzese JL, Das P, et al. Induction chemotherapy selects patients with locally advanced, unresectable pancreatic cancer for optimal benefit from consolidative chemoradiation therapy. Cancer 2007; 110:47-55. [PMID 17538975]
Copyright (c) 2011 Bryan W Chang, Muhammad W Saif
This work is licensed under a Creative Commons Attribution 4.0 International License.
As a member of Publisher International Linking Association, PILA, iMedPub Group’s JOP follows the Creative Commons Attribution License and Scholars Open Access publishing policies. Journal of the Pancreas is the Council Contributor Member of Council of Science Editors (CSE) and following the CSE slogan Education, Ethics, and Evidence for Editors.